About
Revolo Biotherapeutics develops peptide-based immunomodulatory therapies designed to restore immune homeostasis for allergic and autoimmune diseases. Its lead candidates (‘1104 and ‘1805) are in clinical development (Phase 1–2 / Phase 2) for indications including eosinophilic esophagitis, atopic dermatitis, rheumatoid arthritis and ulcerative colitis.
Explore Revolo Biotherapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.